Alterity Therapeutics Ltd (PBN.BE)
| Previous close | 0.0060 |
| Open | 0.0055 |
| Bid | 0.0055 x 0 |
| Ask | 0.0085 x 0 |
| Day's range | 0.0055 - 0.0055 |
| 52-week range | 0.0040 - 0.0115 |
| Volume | |
| Avg. volume | 187 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA)
- Zacks
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
- PR Newswire
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.
